Senzime AB is a Swedish public limited company with its registered office in Uppsala. The company’s share is listed on Nasdaq Stockholm’s Main Market (Small Cap) with the ticker SEZI.
Corporate governance in Senzime is based on applicable laws, regulations and recommendations. The company’s Corporate Governance Report reviews the company’s application of the Swedish Code of Corporate Governance (the Code).
The purpose of Senzime’s corporate governance is to create clear segregation of duties and responsibilities between owners, the Board of Directors and management. Internal governance, controls and risk management over financial reporting are fundamental to Senzime’s operational governance.
Senzime’s decision-making bodies are its shareholders’ meetings, Board of Directors, President and auditors, and based on Swedish law, internal regulations and provisions, the Articles of Association, and are compliant with Nasdaq OMX’s (Small Cap) Rulebook for Issuers.
Senzime Board of Directors is a global team of experts in business development, clinical research and life science development.
Senzime management is a team of people with extensive global experience in the field of medical devices, healthcare and life science.